Moreover, in early-stage GC tumor lesions, a relatively higher amount of PD-1 molecules on CD8+ T cells was found, which indicated that current PD-1 inhibitor ICB might benefit early-stage GC patients. The gene discussed is CD8A; the disease is neoplasm.